Evaluating the safety and immunogenicity of yellow fever vaccines: a systematic review

References

• World Health Organization. Vaccines and vaccination against yellow fever WHO Position Paper – June 2013. Epidemiol Rec. 2013;88(27):269–284. Available from: http://www.who.int/wer/en. Accessed March 23, 2015.
   Google Scholar
• Barrett ADT, Teuwen DE. Yellow fever vaccine – how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21:308–313. doi:10.1016/j.coi.2009.05.018.
   PubMed Web of Science ®Google Scholar
• Stock NK, Boschetti N, Herzog C, Appelhans MS, Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine. 2012;30:989–994. doi:10.1016/j.vaccine.2011.12.057.
   PubMed Web of Science ®Google Scholar
• Pfister M, Kürsteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, et al. Immunogenicity and safety of Berna-YF compared with two other 17D Yellow Fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg. 2005;72(3):339–346.
   PubMed Web of Science ®Google Scholar
• Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–7930. doi:10.4049/jimmunol.0803903.
   PubMed Web of Science ®Google Scholar
• Blom K, Braun M, Ivarsson MA, et al. Temporal dynamics of the primary human t cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190:2150–2158. doi:10.4049/jimmunol.1202234.
   PubMed Web of Science ®Google Scholar
• Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 2011;6(12):e27753. doi:10.1371/journal.pone.0027753.
   PubMed Web of Science ®Google Scholar
• World Health Organization Regional Office for the Western Pacific Region. Immunization Safety Surveillance: Guidelines for Immunization Programme Managers on Surveillance of Adverse Events Following Immunization. 2nd ed. Manila, Philippines: WHO Press; 2013.
   Google Scholar
• Thomas RE, Spragins W, Lorenzetti DL. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria? Vaccine. 2013;31:6201–6209.
   Web of Science ®Google Scholar
• Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine. 2011;29(28):4544–4555.
   PubMed Web of Science ®Google Scholar
• Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review. Curr Drug Saf. 2011;6(3):145–154.
   PubMedGoogle Scholar
• Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. J Trop Med Hyg. 2012;86(2):359–372. doi:10.4269/ajtmh.2012.11-0525.
   Web of Science ®Google Scholar
• Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30:5038–5058.
   PubMed Web of Science ®Google Scholar
• Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5675–5684.
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612.
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5771–5792.
   PubMed Web of Science ®Google Scholar
• O’Conghaile SO, Alsharbaty MJ, McDermott SR, Conlon PJ, Royston MD, Dwyer RC. Fulminant hepatitis and multisystem organ failure following yellow fever vaccination: description of a fatal case. Anaesth Intensive Care. 2014;42(3):423–424.
   Web of Science ®Google Scholar
• Pires-Marczewski FC, Martinez VP, Nemirovsky C, Padula PJ. Intrathecal antibody production in two cases of yellow fever associated neurotropic disease in Argentina. J Med. 2011;83:2208–2212.
   Google Scholar
• Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31:1819–1829.
   PubMed Web of Science ®Google Scholar
• Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril™: a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–1368. doi:10.1586/14760584.2013.836320.
   PubMed Web of Science ®Google Scholar
• de Menezes Martins R, de Lourdes de S Maia M, dos Santos EM, Cruz RL de S, dos Santos PRG, Carvalho SMD, et al. Yellow Fever Vaccine Post-marketing Surveillance in Brazil. Procedia Vaccinol. 2010;2:178–183. doi:10.1016/j.provac.2010.07.012.
   Google Scholar
• Barban V, Girerd Y, Aguirre M, et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine. 2007;25(15):2941–2950.
   PubMed Web of Science ®Google Scholar
• Moulin J-C, Silvano J, Barban V, Riou P, Allain C. Yellow fever vaccine: comparison of the neurovirulence of new 17D-204 Stamaril™ seed lots and RK 168-73 strain. Biologicals. 2013;41:238–246. Available from: http://dx.doi.org/10.1016/j.biologicals.2013.04.005. Accessed March 23, 2015.
   Google Scholar
• Khromava AY, Eidex RB, Weld LH, et al; The Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23:3256–3263.
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–6082.
   PubMed Web of Science ®Google Scholar
• Martin M, Weld LH, Tsai TF, et al; GeoSentinel Yellow Fever Working Group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001;7:945–951.
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005;1:207–214.
   PubMed Web of Science ®Google Scholar
• Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;1:CD010929. doi:10.1002/14651858.CD010929.pub2.
   Google Scholar
• Azevedo L, Lasmar E, Contier F, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14:237–241.
   PubMed Web of Science ®Google Scholar
• Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32:5769–5775. doi:org/10.1016/j.vaccine.2014.08.051.
   PubMed Web of Science ®Google Scholar
• Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31:5798–5805. doi.org/10.1016/j.vaccine.2013.09.030.
   PubMed Web of Science ®Google Scholar
• Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell. 2004;28:244–248.
   PubMedGoogle Scholar
• Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434-44. doi: 10.4269/ajtmh.13-0264. Accessed April 8, 2015.
   PubMed Web of Science ®Google Scholar
• Monath T, Fowler E, Johnson C, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364:1326–1333.
   PubMed Web of Science ®Google Scholar
• Gaspar L, Mendes Y, Yamamura A, et al. Pressure inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods. 2008;150:57–62.
   PubMed Web of Science ®Google Scholar
• Schafer B, Holzer G, Joachimsthaler A, et al. Preclinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One. 2011;6(9):e24505.
   PubMed Web of Science ®Google Scholar